BPC-157 + TB-500: The Wolverine Stack Explained

BPC-157 (Body Protection Compound-157) is a stable gastric peptide studied since the 1990s for its remarkable tissue-repair effects. Its core action is accelerating angiogenesis — the growth of new small blood vessels into damaged tissue, which is step one of any repair: no blood supply, no healing.

Beyond vessel growth, research shows it promotes collagen synthesis, tendon-to-bone healing, and gut-lining repair, and it modulates growth-factor expression. It is one of the few peptides where the oral form genuinely works — but specifically for GI healing; the subcutaneous form is preferred for systemic musculoskeletal injuries.

Studied contexts: tendon and ligament injury, muscle tears, joint degeneration, inflammatory gut conditions, and post-surgical recovery. Its own page covers the full dosing, cycle, and contraindication detail.

TB-500 is the active fragment of thymosin beta-4, a protein that regulates actin — the cellular skeleton protein that cells use to move and reorganize. Upregulating actin promotes cell migration: repair cells physically travel into wounded tissue.

It also reduces inflammation, promotes blood-vessel and dermal repair, and supports tissue remodeling in the weeks after injury. If BPC-157 builds the supply lines, TB-500 delivers and organizes the construction crew.

TB-500 is dosed on a different rhythm than BPC-157 — larger, less frequent doses (2–5 mg twice weekly) because of its longer functional window — which is exactly why the two interleave so cleanly.

Tissue repair is sequential: blood supply first, cell migration second, collagen remodeling third. The Wolverine Stack is powerful because the two components dominate different phases:

The result is full-timeline coverage: acute phase and remodeling phase both stimulated. Anecdotally and in animal research, the combination outperforms either peptide alone — which is why pre-blended vials ("BPC/TB combo," branded KLOW blends) became a product category of their own.

Weight-based math: BPC-157 research dosing is ~3.5 mcg/kg per administration — about 280 mcg for an 80 kg adult — which is why the standard 250–500 mcg range fits nearly everyone. TB-500 runs ~28 mcg/kg weekly divided into two doses. The protocol engine computes exact figures for your weight.

Sample week on the stack

• •Morning: BPC-157 250–500 mcg subcutaneous, ideally near (but not into) the injury site
• •Evening: BPC-157 250–500 mcg second dose
• •Monday & Thursday: TB-500 2–2.5 mg subcutaneous (any time; it does not need to align with BPC doses)
• •Weeks 1–6: continue; weeks 7–10: full break from both

• •Week 1: subtle effects — reduced nagging pain, slightly better tissue tolerance. Repair biology is slow; do not expect visible change.
• •Weeks 2–3: the period most people report the first "it actually feels different" moments — stiffness easing, range of motion creeping back, less pain after load.
• •Weeks 4–6: remodeling phase benefits — strength through the healed range, less re-injury fear. Research protocols stop here; the remaining maturation happens under normal loading.
• •Break weeks: benefits persist. If the injury is not meaningfully better after one full cycle, re-evaluate the diagnosis rather than stacking a second cycle immediately.

Subcutaneous injection delivers to the fat layer, absorbed systemically. Two research strategies: systemic (dosed anywhere, reaches the whole body — appropriate for gut healing, general recovery) and site-near (injected into subcutaneous fat close to the injury, where local concentrations are higher before dilution — common for tendon, ligament, and joint protocols). Site-near is not the same as injecting into the tendon itself; never inject into joints, tendons, or ligaments directly without expert supervision.

• •Bleeding risk: BPC-157 interacts with warfarin and is contraindicated with active bleeding or before surgery — discuss with the prescriber of any anticoagulant.
• •Autoimmune: TB-500's immune-tissue interaction makes it inappropriate for active autoimmune conditions.
• •Pregnancy/breastfeeding: standard hard exclusion for both peptides.
• •Side effects are generally mild: injection-site irritation, transient fatigue, occasional headache or mild dizziness. Severe reactions are rare — stop immediately if they occur.
• •Both peptides lack FDA approval as therapeutic agents; the data base is preclinical and off-label clinical. That is the honest framing of every recovery claim above.

In research and supervised settings, the Wolverine Stack fits: tendon/ligament strains that heal slowly, post-surgical recovery protocols, muscle tears, degenerative joint contexts alongside physical therapy, and inflammatory gut conditions (BPC-157 oral component). It does not replace diagnosis, rehab loading programs, or surgery where surgery is indicated. It is an adjunct to a rehab plan — the best results in every case report sit on top of progressive loading, not instead of it.